Evidence map›Paper›PMID 25299962›Full record

ArticleBiological research2014

Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study.

Lisa Repsold, Thandi Mqoco, Elize Wolmarans, Sandra Nkandeu, Joji Theron, Tomek Piorkowski, Peet du Toit, Dirk van Papendorp, Annie Margaretha Joubert

Open access · goldAbstract read
In one paragraph

Article in Biological research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lisa RepsoldDepartment of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. lisarepsold@yahoo.com.
Thandi MqocoDepartment of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. thandi.mqoco@up.ac.za.
Elize WolmaransDepartment of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. elizewol@yahoo.com.
Sandra NkandeuDepartment of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. sandra.djeukam@up.ac.za.
Joji TheronDepartment of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. joji.theron@up.ac.za.
Tomek PiorkowskiDepartment of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. tomek.piorkowski@up.ac.za.
Peet du ToitDepartment of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. peet.dutoit@up.ac.za.
Dirk van PapendorpDepartment of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. dirk.vanpapendorp@up.ac.za.
Annie Margaretha JoubertDepartment of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. annie.joubert@up.ac.za.
University of Pretoria · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNovel, in silico-designed anticancer compounds were synthesized in our laboratory namely, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16). These compounds were designed to have improved bioavailability when compared to their source compound, 2-methoxyestradiol. This theoretically would be due to their increased binding affinity to carbonic anhydrase II, present in erythrocytes. Since the novel compounds under investigation are proposed to be transported within erythrocytes bound to carbonic anhydrase II, the morphological effect which they may exert on whole blood and erythrocytes is of great significance. A secondary outcome included revision of previously reported procedures for the handling of the whole blood sample. The purpose of this study was twofold. Firstly, the ultrastructural morphology of a healthy female's erythrocytes was examined via scanning electron microscopy (SEM) after exposure to the newly in silico-designed compounds. Morphology of erythrocytes following exposure to ESE-15-ol and ESE-16 for 3 minutes and 24 hours at 22°C were described with the use of SEM. The haemolytic activity of the compounds after 24 hours exposure were also determined with the ex vivo haemolysis assay. Secondly, storage conditions of the whole blood sample were investigated by determining morphological changes after a 24 hour storage period at 22°C and 37°C.

resultsNo significant morphological changes were observed in the erythrocyte morphology after exposure to the novel anticancer compounds. Storage of the whole blood samples at 37°C for 24 hours resulted in visible morphological stress in the erythrocytes. Erythrocytes incubated at 22°C for 24 hours showed no structural deformity or distress.

conclusionsFrom this research the optimal temperature for ex vivo exposure of whole blood samples to ESE-15-ol and ESE-16 for 24 hours was determined to be 22°C. Data from this study revealed the potential of these compounds to be applied to ex vivo study techniques, since no damage occurred to erythrocytes ultrastructure under these conditions. As no structural changes were observed in erythrocytes exposed to ESE-15-ol and ESE-16, further ex vivo experiments will be conducted into the potential effects of these compounds on whole blood. Optimal incubation conditions up to 24 hours for whole blood were established as a secondary outcome.

Indexed as

Computer SimulationAntineoplastic AgentsBiological AvailabilityCarbonic Anhydrase IICarbonic Anhydrase InhibitorsCarrier ProteinsDrug DiscoveryErythrocytesEstradiolEstrenesFemaleHemolysisHumansMicroscopy, Electron, ScanningMiddle AgedQualitative Research2-ethyl-3-O-sulfamoylestra-1,3,5(10)16-tetraene2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-olAntineoplastic AgentsCarbonic Anhydrase IICarbonic Anhydrase InhibitorsCarrier ProteinsEstradiolEstrenesSulfonamides

Identifiers

PMID25299962
PMCPMC4167501
OpenAlexW2114690313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.